Although a retrospective study reported that 60% of patients who developed CDK4/6 inhibitor-induced ILD had pulmonary metastases (23), the extent to which pulmonary metastases and abemaciclib contribute to the development of ILD remains unclear. The gene discussed is CDK4; the disease is interstitial lung disease.